BPC-157 and TB-500 are the two most commonly combined peptides in preclinical recovery and repair research. Each targets different aspects of tissue repair — BPC-157 through the nitric oxide and VEGF pathways, TB-500 through actin regulation and cell migration. Researchers study them together because their mechanisms complement rather than duplicate each other.
What Each Compound Does
BPC-157 is a 15-amino acid peptide derived from gastric juice. Rodent studies show it accelerates healing across gastrointestinal, musculoskeletal, and neurological models. It promotes VEGF expression and modulates nitric oxide synthesis. The most documented applications are gut mucosal repair and tendon healing.
TB-500 (Thymosin Beta-4 fragment) binds G-actin and promotes cell migration and angiogenesis. In rodent models it accelerates wound closure and shows effects in cardiac and muscle tissue. Unlike BPC-157, its primary mechanism is cytoskeletal — it affects how cells move and reorganise during repair.
Why Researchers Study Them Together
The rationale for combining them comes from their distinct and potentially synergistic mechanisms. BPC-157 promotes vascularisation and modulates inflammatory signalling. TB-500 drives cell migration and matrix remodelling. In tissue repair, both processes happen simultaneously — new blood vessel formation and cellular reorganisation occur together. Preclinical research on the combination (often called the GLOW or KLOW blend) examines whether the effects are additive.
The KLOW blend combines BPC-157, TB-500, GHK-Cu, and KPV. Published Janoshik-verified tests of this combination are available from multiple suppliers, confirming compound identity in blended formulations.
Research Protocol Considerations
Both compounds are administered via subcutaneous or intramuscular injection in rodent studies. Typical rodent doses in published literature range from 1–10 mcg/kg for BPC-157 and 500 mcg–2mg for TB-500 in various models. These figures are for reference to published research only — not dosing guidance.
Storage: both are lyophilised powders reconstituted in bacteriostatic water. Store at −20°C before reconstitution and 2–8°C after. Use within 28 days of reconstitution.
Sourcing for Research
FenaLife supplies both compounds individually, each with Janoshik third-party COA. BPC-157 10mg and TB-500 10mg are available separately. For stacking research, ordering both ensures independent purity verification for each compound.
Frequently Asked Questions
Is there published research on BPC-157 and TB-500 combined?
Research on the combination is less extensive than on each compound individually. The KLOW and GLOW blends have been verified by Janoshik as accurately labelled, and some preclinical studies have examined combined tissue repair effects.
Do BPC-157 and TB-500 interact negatively?
No negative interactions have been reported in preclinical literature. Their mechanisms operate through different pathways.
Free shipping available?
Yes — free on all orders over $100.
For research use only. Not for human consumption, injection, or ingestion.